Survival Up With Bortezomib in T-Cell Lymphoblastic Lymphoma

FRIDAY, March 25, 2022 -- Adding the proteasome inhibitor bortezomib to a chemotherapy regimen improves survival in children with T-cell lymphoblastic lymphoma (T-LL), according to a study published online March 10 in the Journal of Clinical...

Source: Drugs.com - Pharma News - March 25, 2022 Category: Pharmaceuticals Source Type: news